Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1080. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.98 |
| ▸ | CDK7 | P50613 | 3/20 | 0.98 |
| ▸ | CDK1 | P06493 | 2/20 | 0.98 |
| ▸ | CDK2 | P24941 | 2/20 | 0.98 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.98 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.98 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.98 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.98 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.98 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.98 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.98 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.98 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.98 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.98 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.98 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.98 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1080 SCHEMBL30298327 | 0.99 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL394519 | 0.99 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29374248 | 0.99 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL3701569 | 0.99 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29361806 | 0.99 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2684436 | 0.94 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL27755135 | 0.94 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2685061 | 0.93 | CDK7 (0.88) | CDK7CDK1CDK2DYRK3GSK3B | |
| Hydrochloric Acid SCHEMBL4058368 | 0.92 | CDK7 (0.84) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2686165 | 0.92 | CDK7 (0.86) | CDK7CDK1CDK2DYRK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| US-8101750-B2 | Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile 701 | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-20100286392-A1 | PROCESS FOR THE MANUFACTURING OF THE COMPOUND 2-HYDROXY-3-[5-(MORPHOLIN-4-YLMETHYL)PYRIDIN-2-YL]1H-INDOLE-5-CARBONITRILE 701 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| CN-101679353-A | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| EP-2146979-A1 | A NEW PROCESS FOR THE MANUFACTURING OF THE COMPOUND 2-HYDROXY-3-[5-(MORPHOLIN-4-YLMETHYL)PYRIDIN-2-YL]1H-INDOLE-5-CARBONITRILE 701 | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008130312-A1 | A NEW PROCESS FOR THE MANUFACTURING OF THE COMPOUND 2-HYDROXY-3-[5-(MORPHOLIN-4-YLMETHYL)PYRIDIN-2-YL]1H-INDOLE-5-CARBONITRILE 701 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286392-A1 | PROCESS FOR THE MANUFACTURING OF THE COMPOUND 2-HYDROXY-3-[5-(MORPHOLIN-4-YLMETHYL)PYRIDIN-2-YL]1H-INDOLE-5-CARBONITRILE 701 | IDO1, IDO2, HCN2 | GSK3B 734/4885CDK7 2396/4885CDK1 1427/4885 |
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | GSK3B 1261/4885CDK7 444/4885CDK1 263/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | GSK3B 1078/4885CDK7 1005/4885CDK1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.